Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846752 | 0.86 | ADRB1 (0.53) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL3744956 | 0.85 | PNP (0.60) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL3425761 | 0.85 | PNP (0.57) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL8506519 | 0.85 | CYP1A2 (0.55) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL888195 | 0.85 | CYP1A2 (0.49) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL7026017 | 0.84 | PNP (0.51) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL20567028 | 0.84 | PNP (0.56) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL1533270 | 0.83 | ADORA3 (0.62) | ADORA3ADORA1 | |
| SCHEMBL6882745 | 0.83 | ADORA3 (0.62) | ADORA3ADORA1 | |
| SCHEMBL5360845 | 0.83 | CYP1A2 (0.71) | PNPLMNATP53HTTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213279-A1 | O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS AND BETA-GLUCURONIDASE CLEAVABLE PRODRUGS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE | 2007-09-13 | — | — | US | claimed |
| EP-1807438-A1 | BETA-GLUCURONIDASE CLEAVABLE PRODRUGS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006029065-A1 | BETA-GLUGURONIDASE CLEAVABLE PRODRUGS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS | GOVERMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-03-16 | — | — | WO | claimed |
| US-12274735-B2 | IL-4-fusion formulations for treatment of central nervous system (CNS) tumors | MEDICENNA THERAPEUTICS INC. (CA) | 2025-04-15 | — | — | US | disclosed |
| US-8188055-B2 | Inactivators of O6-alkylguanine-DNA alkyltransferase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-05-29 | — | — | US | disclosed |
| US-7825096-B2 | O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825096-B2 | O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100204172-A1 | INACTIVATORS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-08-12 | — | — | US | disclosed |
| WO-2010028781-A1 | 8- AND 6,8-SUBSTITUTED-2'-DEOXYGUANOSINES AND USES THEREOF | Universität Zürich (CH) | 2010-03-18 | — | — | WO | disclosed |
| EP-2134715-A2 | O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008137207-A2 | INACTIVATORS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1807438-A1 | BETA-GLUCURONIDASE CLEAVABLE PRODRUGS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006029065-A1 | BETA-GLUGURONIDASE CLEAVABLE PRODRUGS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS | GOVERMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1054890-B1 | OLIGODEOXYRIBONUCLEOTIDES COMPRISING O6-BENZYLGUANINE AND THEIR USE | US HEALTH (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1054890-A1 | OLIGODEOXYRIBONUCLEOTIDES COMPRISING O6-BENZYLGUANINE AND THEIR USE | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999041269-A1 | OLIGODEOXYRIBONUCLEOTIDES COMPRISING O6-BENZYLGUANINE AND THEIR USE | THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-08-19 | — | — | WO | disclosed |
| EP-0523100-B1 | O6 -BENZYLATED GUANINE, GUANOSINE AND 2'-DEOXYGUANOSINE COMPOUNDS POSSESSING O6 -ALKYLGUANINE-DNA ALKYLTRANSFERASE DEPLETING ACTIVITY | US HEALTH (US) | 1996-08-28 | — | — | EP | disclosed |
| EP-0523100-A4 | O?6 -BENZYLATED GUANINE, GUANOSINE AND 2'-DEOXYGUANOSINE COMPOUNDS POSSESSING O?6 -ALKYLGUANINE-DNA ALKYLTRANSFERASE DEPLETING ACTIVITY | US HEALTH (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0523100-A1 | O?6 -BENZYLATED GUANINE, GUANOSINE AND 2'-DEOXYGUANOSINE COMPOUNDS POSSESSING O?6 -ALKYLGUANINE-DNA ALKYLTRANSFERASE DEPLETING ACTIVITY. | US HEALTH (US) | 1993-01-20 | — | — | EP | disclosed |
| WO-1991013898-A1 | O6-BENZYLATED GUANINE, GUANOSINE AND 2'-DEOXYGUANOSINE COMPOUNDS POSSESSING O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE DEPLETING ACTIVITY | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1991-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204172-A1 | INACTIVATORS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | AGT, UNG, DPYD | PNP 113/4885LMNA 2712/4885TP53 187/4885 |
| US-20070213279-A1 | O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS AND BETA-GLUCURONIDASE CLEAVABLE PRODRUGS | UNG, OGG1, MPG | PNP 20/4885LMNA 1100/4885TP53 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.